PRECIGEN, INC. Impairment of Long-Lived Assets Held-for-use
PRECIGEN, INC. (PGEN) reported Impairment of Long-Lived Assets Held-for-use of $598.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-25
- PRECIGEN, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-06-30 was $110.00K.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-03-31 was $110.00K.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for the quarter ending 2020-06-30 was $9.91M.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for the quarter ending 2019-12-31 was $0.00.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $598.00K, a 34.38% increase from fiscal 2023.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $445.00K, a 30.25% decline from fiscal 2022.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $638.00K, a 17.50% increase from fiscal 2021.
- PRECIGEN, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $543.00K, a 33.29% decline from fiscal 2020.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $598.00K 10-K · filed 2026-03-25 | ||||
| 2024-06-30 | $110.00K 10-K · filed 2025-03-19 | $110.00K 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $110.00K 10-Q · filed 2024-11-14 | ||||
| 2023-12-31 | $445.00K 10-K · filed 2026-03-25 | ||||
| 2022-12-31 | $638.00K 10-K · filed 2025-03-19 | ||||
| 2021-12-31 | $543.00K 10-K · filed 2024-03-19 | ||||
| 2020-12-31 | $814.00K 10-K · filed 2023-03-06 | $920.00K 10-K · filed 2021-03-01 | |||
| 2020-06-30 | $9.91M 10-Q · filed 2020-08-10 | $9.91M 10-Q · filed 2020-08-10 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $448.00K derived: sum of 2 quarters · filed 2022-03-01 | $448.00K 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $448.00K 10-Q · filed 2020-11-09 | $448.00K 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |